Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus
Published . Updated .
Nxera Pharma just put Q2 2026 under the microscope, and the real story is margins, not hype. The stock came into the release at ¥1,440 after a powerful 90 day climb, so expectations were loaded. Reported revenue of ¥7,654m sat against a small net loss of ¥202m, which keeps the
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story.
- EWJ iShares MSCI Japan ETF-0.2% 30d
iShares MSCI Japan ETF holds stocks listed in Japan, which this story is about (“tse”).
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- PFE Pfizer+8.9% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
- MRK Merck+3.2% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| XBINo price data for this ticker | — | — | — | — | — | — | — |
| EWJNo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus Yahoo Finance
Source: Yahoo Finance
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 58 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 37 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 54 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 58 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 58 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 72 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 74 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies tied to this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 1 Nov 2026 story “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story
- XBI Spdr Series Trust
In “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story
- EWJ Ishares
In “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus,” Ishares (EWJ) is linked, with no stored direction, medium confidence. Reason on file: iShares MSCI Japan ETF holds stocks listed in Japan, which this story is about (“tse”)
- LLY Eli Lilly
Eli Lilly (LLY) is linked, with no stored direction, medium confidence in the 1 Nov 2026 story “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus.” Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
- JNJ Johnson & Johnson
For “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
- PFE Pfizer
For “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
- MRK Merck
Merck (MRK) is linked, with no stored direction, medium confidence in the 1 Nov 2026 story “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus.” Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharma” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
On 1 Nov 2026, “Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus” is the story that connects Select Sector Spdr Tr (XLV) to this story.
The link for Select Sector Spdr Tr (XLV) is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharma” (pharma and health) in this story
Price levels for Select Sector Spdr Tr (XLV)
EWJ traded between 95.11 and 99.98 across 18 sessions. The latest close on file is 97.33.
A simple score for Select Sector Spdr Tr (XLV)
46 out of 100
“Nxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In Focus” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.